A Study of LY2484595 on the Electrical Activity of the Heart
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect on the electrical activity of the heart
as measured by an electrocardiogram (ECG) after dosing with 10 days of LY2484595 compared to
10 days of placebo in relation to a single dose of moxifloxacin. Information about any side
effects that occur will also be collected.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Evacetrapib Moxifloxacin Norgestimate, ethinyl estradiol drug combination